SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 702.90-3.1%3:58 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Felix B who wrote (2260)1/24/2018 11:22:27 PM
From: Miljenko Zuanic  Read Replies (2) of 3559
 
I am unclear too. Prevalence of HoHF in US is ~900 subjects, no room for many players, hard to recover investment.
For HeHF... 1500, as better agent, may be better option,...but it will be against praluent/repatha/MDCO...again no much room to compete. They should re-invest their tax-relief money somewhere else, where chances are better.

Sanofi is spending money on stupid acquisitions, glad that they are out of REGN (except IO).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News